Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Picchio

Showing results (111-120 of 181) with videos related to

Pageof 19
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 31, 2007
Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamineRoswitha Beck, Barbara Röper, Janette Maria Carlsen, et al.
Current Radiopharmaceuticals|November 10, 2017
18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and ImmunohistochemistryPaola Mapelli, Valentino Bettinardi, Federico Fallanca, et al.
Journal of Digital Imaging|January 29, 2022
Evaluation of a 2D UNet-Based Attenuation Correction Methodology for PET/MR Brain StudiesLuca Presotto, Valentino Bettinardi, Matteo Bagnalasta, et al.
World Journal of Urology|May 13, 2018
Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancerAndrei Fodor, Andrea Lancia, Francesco Ceci, et al.
European Urology|August 23, 2011
Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83Stefano Fanti, Bernd Krause, Wolfgang Weber, et al.
Tumori|October 26, 2010
[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 monthsFilippo Alongi, Stefano Schipani, Ana Maria Samanes Gajate, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 5, 2023
External validation of an <sup>18</sup>F-FDG-PET radiomic model predicting survival after radiotherapy for oropharyngeal cancerMartina Mori, Chiara Deantoni, Michela Olivieri, et al.
The Journal of Urology|July 21, 2010
[11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imagingGiampiero Giovacchini, Maria Picchio, Alberto Briganti, et al.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|November 24, 2004
Conotruncal heart defects: impact of genetic syndromes on immediate operative mortalitySilvia Anaclerio, Vincenzo Di Ciommo, Guido Michielon, et al.
Nuclear Medicine Communications|February 20, 2010
High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative stagingMaria Picchio, Giorgia Mangili, Ana M Samanes Gajate, et al.
Pageof 19

Showing results (111-120 of 181) with videos related to

Sort By:
Pageof 19
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 31, 2007
Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamineRoswitha Beck, Barbara Röper, Janette Maria Carlsen, et al.
Current Radiopharmaceuticals|November 10, 2017
18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and ImmunohistochemistryPaola Mapelli, Valentino Bettinardi, Federico Fallanca, et al.
Journal of Digital Imaging|January 29, 2022
Evaluation of a 2D UNet-Based Attenuation Correction Methodology for PET/MR Brain StudiesLuca Presotto, Valentino Bettinardi, Matteo Bagnalasta, et al.
World Journal of Urology|May 13, 2018
Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancerAndrei Fodor, Andrea Lancia, Francesco Ceci, et al.
European Urology|August 23, 2011
Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83Stefano Fanti, Bernd Krause, Wolfgang Weber, et al.
Tumori|October 26, 2010
[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 monthsFilippo Alongi, Stefano Schipani, Ana Maria Samanes Gajate, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 5, 2023
External validation of an <sup>18</sup>F-FDG-PET radiomic model predicting survival after radiotherapy for oropharyngeal cancerMartina Mori, Chiara Deantoni, Michela Olivieri, et al.
The Journal of Urology|July 21, 2010
[11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imagingGiampiero Giovacchini, Maria Picchio, Alberto Briganti, et al.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|November 24, 2004
Conotruncal heart defects: impact of genetic syndromes on immediate operative mortalitySilvia Anaclerio, Vincenzo Di Ciommo, Guido Michielon, et al.
Nuclear Medicine Communications|February 20, 2010
High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative stagingMaria Picchio, Giorgia Mangili, Ana M Samanes Gajate, et al.
Pageof 19